Zofranlegal.com has reported that in just a few days, on April 14th, 2016, the plaintiffs involved in the ongoing Zofran litigation will file their Master Complaint for MDL 2657. In addition to this, they will also provide the defendant, GlaxoSmithKline, with a Short Form Complaint which will provide the company with the names of all plaintiffs, the form of Zofran which they used (oral or I.V.), which state the drug was prescribed in, the state in which the child named in the complaint was born in, and the injuries being claimed.
The plaintiffs have also requested that the Master Answer, which will ultimately be filed by GSK, be returned no later than May 17th, 2016.
Each complaint filed in MDL 2657 alleges that the anti-emetic drug Zofran caused a birth defect when an unborn child was exposed to it while still in the womb. The drug has been prescribed to millions of women throughout America as a treatment for morning sickness, despite the fact that the U.S. Food and Drug Administration had not approved the drug for this use. The department did grant its approval for the drug, but only as a treatment for nausea and vomiting after chemotherapy, radiation, and anesthesia.
It is also being alleged that GSK promoted the drug as a treatment for morning sickness and that this marketing was “unlawful” because the FDA had not approved the drug as a treatment for this condition. Plaintiffs claim that it was this advertising decision which led to the mother in each case being prescribed the drug, a decision which ultimately led to a birth defect in a child. Claimed birth defects include cleft lip, cleft palate, ventricular septal defect, atrial septal defect, clubfoot, kidney defects, and respiratory distress syndrome.
The number of claims in MDL 2657 has reached more than 230 and new lawsuits are being filed regularly. The lawyers of Monheit Law are offering complimentary consultations to anyone who believes their child was harmed by the Zofran. To learn more, contact Michael Monheit at (877) 620-8411.
Sponsored by an alliance of attorneys, ZofranLegal.com is a resource for parents, families and birth defect survivors interested in learning more about litigation surrounding the nausea drug Zofran and its link to increased risks of major birth defects.
1368 Barrowdale Road, Rydal, PA 19046
April 30, 2016 – Lawsuit Alleges Invokana Side Effects Can Include Diabetic Ketoacidosis, a Life-Threatening Condition Related to Too Much Acid in the Body
April 29, 2016 – Zofran Lawsuit Update: Plaintiffs Question Why GSK Hasn’t Faced Stiffer Penalties
April 27, 2016 – Arkansas Mother Files Zofran Lawsuit Claiming Multiple Defects Caused By Drug
April 25, 2016 – Zofran Lawsuit Plaintiffs Applaud FDA’s Decision Regarding Folic Acid
April 22, 2016 – MyFoxBoston News Release Discusses Concerning Zofran Birth Defect Lawsuits And Drug Safety
April 22, 2016 – Zofran Lawsuit Plaintiffs Note Results Of Japanese Animal Studies Linking Birth Defects To Drug
April 22, 2016 – A Look Back At America’s First Zofran Lawsuit
April 21, 2016 – Significant Increase In Birth Defect Development Investigated By Washington State Amid Mounting Zofran Lawsuits
April 21, 2016 – Zofran Lawsuit Plaintiffs Make Note Of Canadian Label Differences On Drug Which Warn Of Use During Pregnancy
April 20, 2016 – Zofran Lawsuit Plaintiff Claims Infant’s Cleft Palate, Clubfoot, And Respiratory Distress Caused By Drug Exposure
